Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations

British Journal of Cancer
M BramleyE Anderson

Abstract

There is considerable interest in whether anti-oestrogens can be used to prevent breast cancer in women bearing mutations in the BRCA1 and BRCA2 genes. The effects of oestradiol (E2), tamoxifen (TAM) and fulvestrant (FUL) on proliferation and steroid receptor expression were assessed in normal breast epithelium taken from women at varying risks of breast cancer and implanted into athymic nude mice, which were treated with E2 in the presence and absence of TAM or FUL. Tissue samples were taken at various time points thereafter for assessment of proliferative activity and expression of oestrogen and progesterone receptors (ERalpha and PgR) by immunohistochemistry. Oestradiol increased proliferation in the breast epithelium from women carrying mutations in the BRCA1/2 genes, those otherwise at increased risk and those at population risk of breast cancer. This increase was reduced by both TAM and FUL in all risk groups. In the absence of E2, PgR expression was reduced in all risk groups but significantly more so in the BRCA-mutated groups. Subsequent E2 treatment caused a rapid, complete induction of PgR expression in the population-risk group but not in the high-risk or BRCA-mutated groups in which PgR induction was significantly ...Continue Reading

References

May 17, 1995·Journal of the National Cancer Institute·C K OsborneR I Nicholson
May 20, 2000·Journal of Mammary Gland Biology and Neoplasia·L A Chodosh
Mar 16, 2001·Breast Cancer Research : BCR·S R Lakhani
Jul 31, 2001·Journal of Clinical Pathology·P A MoteC L Clarke
Aug 30, 2001·Current Biology : CB·P Kerr, A Ashworth
Sep 20, 2001·Seminars in Cancer Biology·J L Hopper
Sep 20, 2001·Seminars in Cancer Biology·C X Deng, S G Brodie
Oct 5, 2001·Trends in Genetics : TIG·S G Brodie, C X Deng
Nov 17, 2001·JAMA : the Journal of the American Medical Association·M C KingUNKNOWN National Surgical Adjuvant Breast and Bowel Project
Mar 29, 2002·Environmental and Molecular Mutagenesis·Timothy R Rebbeck
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sunil R LakhaniDouglas F Easton
May 25, 2002·The New England Journal of Medicine·Timothy R RebbeckUNKNOWN Prevention and Observation of Surgical End Points Study Group
Feb 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zsofia Kote-JaraiRos Eeles
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kelly MetcalfeSteven A Narod
Jun 17, 2004·Molecular and Cellular Biology·Mahnaz RazandiEllis R Levin

❮ Previous
Next ❯

Citations

Jun 8, 2007·Breast Cancer Research : BCR·Kathleen ConwayRobert C Millikan
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leslie R Schover
Sep 28, 2007·Nature Clinical Practice. Oncology·Dimitrios H Roukos, Evangelos Briasoulis
Dec 29, 2012·Cancer Causes & Control : CCC·Jayeon Kim, Kutluk Oktay
Dec 24, 2018·Cancers·Joanne Kotsopoulos
Oct 30, 2013·Breast Cancer Research and Treatment·Myriam VilascoUNKNOWN BRACAPS

❮ Previous
Next ❯

Methods Mentioned

BETA
prophylactic oophorectomy
biopsy

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.